Emergent BioSolutions Inc. (EBS) Analysts See $0.59 EPS; Ardsley Advisory Partners Has Trimmed By $700,000 Its Alexion Pharmaceuticals (ALXN) Position

February 16, 2018 - By reb123z

Analysts expect Emergent BioSolutions Inc. (NYSE:EBS) to report $0.59 EPS on February, 22.They anticipate $0.15 EPS change or 20.27% from last quarter’s $0.74 EPS. EBS’s profit would be $28.73 million giving it 20.83 P/E if the $0.59 EPS is correct. After having $0.73 EPS previously, Emergent BioSolutions Inc.’s analysts see -19.18% EPS growth. The stock increased 1.26% or $0.61 during the last trading session, reaching $49.17. About 248,030 shares traded. Emergent BioSolutions Inc. (NYSE:EBS) has declined 23.64% since February 16, 2017 and is downtrending. It has underperformed by 40.34% the S&P500.

Ardsley Advisory Partners decreased Alexion Pharmaceuticals Inc (ALXN) stake by 2.83% reported in 2017Q3 SEC filing. Ardsley Advisory Partners sold 5,000 shares as Alexion Pharmaceuticals Inc (ALXN)’s stock declined 11.63%. The Ardsley Advisory Partners holds 171,500 shares with $24.06M value, down from 176,500 last quarter. Alexion Pharmaceuticals Inc now has $27.20B valuation. The stock decreased 0.40% or $0.49 during the last trading session, reaching $122.71. About 2.60M shares traded or 21.89% up from the average. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has declined 18.12% since February 16, 2017 and is downtrending. It has underperformed by 34.82% the S&P500.

Ardsley Advisory Partners increased Expedia Inc Del (NASDAQ:EXPE) stake by 41,500 shares to 46,500 valued at $6.69M in 2017Q3. It also upped Hi (NYSE:HCLP) stake by 75,000 shares and now owns 635,000 shares. I D Systems Inc (NASDAQ:IDSY) was raised too.

Among 29 analysts covering Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), 24 have Buy rating, 0 Sell and 5 Hold. Therefore 83% are positive. Alexion Pharmaceuticals Inc. had 100 analyst reports since July 27, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Friday, February 9 by Deutsche Bank. As per Monday, July 17, the company rating was maintained by Nomura. The firm earned “Equal-Weight” rating on Friday, July 29 by Barclays Capital. UBS maintained it with “Buy” rating and $223 target in Friday, July 31 report. As per Wednesday, September 13, the company rating was maintained by BMO Capital Markets. The rating was maintained by Stifel Nicolaus with “Buy” on Thursday, July 27. The stock of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) earned “Buy” rating by Stifel Nicolaus on Friday, December 11. Morgan Stanley upgraded the shares of ALXN in report on Thursday, May 25 to “Overweight” rating. As per Friday, February 17, the company rating was maintained by RBC Capital Markets. The rating was initiated by Suntrust Robinson on Thursday, January 7 with “Buy”.

Since August 28, 2017, it had 0 insider purchases, and 14 sales for $6.68 million activity. 4,787 shares were sold by O’Neill Julie, worth $556,776. Clancy Paul J had sold 6,079 shares worth $707,048. 835 shares were sold by Veneman Ann M, worth $121,751 on Tuesday, September 5. 3,363 shares valued at $389,099 were sold by Moriarty John B on Tuesday, February 6. Another trade for 1,651 shares valued at $192,028 was made by Goff Brian on Tuesday, February 6. Wagner Heidi L also sold $76,805 worth of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) shares. Shares for $169,696 were sold by Franchini Indrani Lall.

Investors sentiment decreased to 1.17 in 2017 Q3. Its down 0.20, from 1.37 in 2017Q2. It dived, as 36 investors sold ALXN shares while 174 reduced holdings. 78 funds opened positions while 167 raised stakes. 206.89 million shares or 0.54% less from 208.01 million shares in 2017Q2 were reported. Ny State Common Retirement Fund holds 0.1% or 566,549 shares in its portfolio. 4,744 were accumulated by Keybank National Association Oh. 2,398 are held by Intrust Bankshares Na. Creative Planning has 16,131 shares for 0.01% of their portfolio. Point72 Asset Management LP stated it has 0.04% in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Goldman Sachs Group Inc holds 0.12% in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) or 3.46M shares. Quinn Opportunity Prns Lc reported 1,500 shares. Bb Biotech Ag owns 1.35M shares or 5.26% of their US portfolio. Factory Mutual Co stated it has 175,300 shares or 0.27% of all its holdings. At Natl Bank reported 0.08% stake. Rathbone Brothers Public Limited Company holds 0.01% in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) or 2,040 shares. City Hldg, West Virginia-based fund reported 38 shares. Westfield Cap Mgmt Lp invested 0.49% of its portfolio in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Regions Corporation holds 2,510 shares. Mitsubishi Ufj Securities Holdings Communications reported 360 shares.

Among 5 analysts covering Emergent Biosolutions (NYSE:EBS), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Emergent Biosolutions had 8 analyst reports since August 10, 2015 according to SRatingsIntel. Wells Fargo initiated the shares of EBS in report on Friday, February 19 with “Outperform” rating. The stock of Emergent BioSolutions Inc. (NYSE:EBS) earned “Hold” rating by Cowen & Co on Friday, July 14. Zacks upgraded it to “Hold” rating and $39 target in Monday, August 10 report. Singular Research maintained Emergent BioSolutions Inc. (NYSE:EBS) on Tuesday, June 28 with “Buy” rating. Chardan Capital Markets initiated it with “Buy” rating and $47 target in Friday, April 15 report. The firm has “Buy” rating by Singular Research given on Monday, March 28.

Investors sentiment increased to 1.69 in Q3 2017. Its up 0.12, from 1.57 in 2017Q2. It is positive, as 11 investors sold Emergent BioSolutions Inc. shares while 48 reduced holdings. 34 funds opened positions while 66 raised stakes. 33.90 million shares or 1.32% less from 34.36 million shares in 2017Q2 were reported. Clarivest Asset Ltd Com owns 84,433 shares for 0.08% of their portfolio. Legal And General Group Public Ltd has invested 0% in Emergent BioSolutions Inc. (NYSE:EBS). Ls Investment Advsrs Ltd Liability Corp stated it has 0% of its portfolio in Emergent BioSolutions Inc. (NYSE:EBS). Convergence Inv Prns Lc accumulated 51,066 shares. Rhumbline Advisers invested in 70,829 shares or 0.01% of the stock. The California-based First Quadrant Limited Partnership Ca has invested 0% in Emergent BioSolutions Inc. (NYSE:EBS). California Pub Employees Retirement Sys, California-based fund reported 52,276 shares. Yorktown Mngmt And Research holds 0.09% or 8,600 shares. Sei Investments has invested 0% of its portfolio in Emergent BioSolutions Inc. (NYSE:EBS). Profund Advsr Limited Liability Company, a Maryland-based fund reported 5,478 shares. Teachers Retirement Systems Of The State Of Kentucky owns 120,306 shares or 0.06% of their US portfolio. The California-based Schwab Charles Inv has invested 0.02% in Emergent BioSolutions Inc. (NYSE:EBS). Wellington Mngmt Llp has 0% invested in Emergent BioSolutions Inc. (NYSE:EBS) for 21,795 shares. Boston Advsrs Ltd Llc reported 14,465 shares. Piedmont Investment Advsr Limited Liability reported 0.01% in Emergent BioSolutions Inc. (NYSE:EBS).

Since August 15, 2017, it had 0 buys, and 14 insider sales for $10.04 million activity. Hauer Jerome M sold $391,787 worth of stock or 7,729 shares. Another trade for 15,000 shares valued at $598,770 was sold by Abdun-Nabi Daniel. The insider Havey Adam sold 7,885 shares worth $292,243. Another trade for 16,439 shares valued at $616,463 was made by El-Hibri Fuad on Thursday, September 7. On Tuesday, December 12 the insider Richard Ronald sold $1.07 million.

Emergent BioSolutions Inc. focuses on the development, manufacture, and commercialization of medical countermeasures that address public health threats. The company has market cap of $2.39 billion. The Company’s products address public health threats primarily chemical, biological, radiological, nuclear, and explosive-related threats, as well as infectious diseases. It has a 27.38 P/E ratio. The company's marketed products include BioThrax, an anthrax vaccine; Anthrasil, a polyclonal antibody for the treatment of inhalational anthrax; BAT for the treatment of botulinum disease; vaccinia immune globulin intravenous that addresses adverse events from smallpox vaccination; reactive skin decontamination lotion kit for the removal or neutralization of chemical warfare agents; and Trobigard, an auto-injector device designed for intramuscular self-injection of atropine sulfate and obidoxime chloride.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 reb123z

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: